Stephen P. Schoenberger

Stephen P. Schoenberger

Auto-generated profile, based on publicly available information

Stephen P. Schoenberger

Centers for Autoimmunity and Inflammation, Vaccine Design, and Cancer Immunotherapy, La Jolla Institute for Immunology, La Jolla, USA

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1998 in Nature
Verified
Journal Article
Closed access
PDF file
SSStephen P. Schoenberger
Stephen P. Schoenberger
RTRene E. M. Toes
Rene E. M. Toes
EVEllen I. H. van der Voort
Ellen I. H. van der Voort
RORienk Offringa
Rienk Offringa
CMCornelis J. M. Melief
Cornelis J. M. Melief

9 February 2003 in Nature
Verified
Journal Article
Closed access
EJEdith Janssen
Edith Janssen
ELEdward E. Lemmens
Edward E. Lemmens
TWTom Wolfe
Tom Wolfe
UCUrs Christen
Urs Christen
MHMatthias G. von Herrath
Matthias G. von Herrath
SSStephen P. Schoenberger
Stephen P. Schoenberger

31 July 2011 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SFSonia Feau
Sonia Feau
RARamon Arens
Ramon Arens
STSusan Togher
Susan Togher
SSStephen P Schoenberger
Stephen P Schoenberger

28 April 2010 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
RARamon Arens
Ramon Arens
SSStephen P. Schoenberger
Stephen P. Schoenberger

1 January 2012 in Nature Communications
Verified
Journal Article
Open access
PDF file
SFSonia Feau
Sonia Feau
ZGZacarias Garcia
Zacarias Garcia
RARamon Arens
Ramon Arens
HYHideo Yagita
Hideo Yagita
JBJannie Borst
Jannie Borst
SSStephen P. Schoenberger
Stephen P. Schoenberger
CD8+ cytotoxic T lymphocytes are critical components of immunity against infectious pathogens, tumours, and in the case of pathogenic autoimmunity, normal self tissues. CD4+ T (TH) cells provide 'help' to CD8+ cytotoxic T lymphocytes during priming by first activating antigen-presenting cells via CD40–CD40L interactions. Here we show that, after immunization with either a noninflammatory, nonreplicating antigen or an overtly inflammatory replicating antigen, CD8+ cytotoxic T lymphocytes prevented from receiving a signal through CD27 during priming subsequently exhibit a specific defect in their capacity for secondary expansion that can be rescued by the absence of TRAIL. Thus, the 'help message' is transmitted to CD8+ T cells via CD70–CD27 signals, enabling them to undergo secondary expansion and avoid TRAIL-mediated apoptosis on re-stimulation. These findings complete our understanding of the cellular interactions through which TH is provided to CD8+ cytotoxic T lymphocytes during priming.

3 July 2023 in Nature Immunology
Verified
Journal Article
Open access
PDF file
SBSpencer E. Brightman
Spencer E. Brightman
ABAngelica Becker
Angelica Becker
RTRukman R. Thota
Rukman R. Thota
MNMartin S. Naradikian
Martin S. Naradikian
LCLeila Chihab
Leila Chihab
SSStephen P. Schoenberger
Stephen P. Schoenberger
CD4+T cells play key roles in a range of immune responses, either as direct effectors or through accessory cells, including CD8+T lymphocytes. In cancer, neoantigen (NeoAg)-specific CD8+T cells capable of direct tumor recognition have been extensively studied, whereas the role of NeoAg-specific CD4+T cells is less well understood. We have characterized the murine CD4+T cell response against a validated NeoAg (CLTCH129>Q) expressed by the MHC-II-deficient squamous cell carcinoma tumor model (SCC VII) at the level of single T cell receptor (TCR) clonotypes and in the setting of adoptive immunotherapy. We find that the natural CLTCH129>Q-specific repertoire is diverse and contains TCRs with distinct avidities as measured by tetramer-binding assays and CD4 dependence. Despite these differences, CD4+T cells expressing high or moderate avidity TCRs undergo comparable in vivo proliferation to cross-presented antigen from growing tumors and drive similar levels of therapeutic immunity that is dependent on CD8+T cells and CD40L signaling. Adoptive cellular therapy (ACT) with NeoAg-specific CD4+T cells is most effective when TCR-engineered cells are differentiated ex vivo with IL-7 and IL-15 rather than IL-2 and this was associated with both increased expansion as well as the acquisition and stable maintenance of a T stem cell memory (TSCM)-like phenotype in tumor-draining lymph nodes (tdLNs). ACT with TSCM-like CD4+T cells results in lower PD-1 expression by CD8+T cells in the tumor microenvironment and an increased frequency of PD-1+CD8+T cells in tdLNs. These findings illuminate the role of NeoAg-specific CD4+T cells in mediating antitumor immunity via providing help to CD8+T cells and highlight their therapeutic potential in ACT.